Compounds, compositions and methods for the treatment of inflammatory diseases
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/12
A61K-031/135
A61K-031/075
A61K-031/05
출원번호
US-0268170
(2011-10-07)
등록번호
US-8754133
(2014-06-17)
발명자
/ 주소
Sanders, Virginia
Cummings, Joel
Snow, Alan D
출원인 / 주소
ProteoTech, Inc.
대리인 / 주소
Eagen, Rebecca
인용정보
피인용 횟수 :
0인용 특허 :
42
초록▼
A method of inhibiting the inflammatory process, the method comprising administering to a mammal suffering from inflammation a therapeutically effective amount of a pharmaceutical composition comprising a compound where: R is a C1-C10 alkylene group, in which, when the number of carbon atoms is at
A method of inhibiting the inflammatory process, the method comprising administering to a mammal suffering from inflammation a therapeutically effective amount of a pharmaceutical composition comprising a compound where: R is a C1-C10 alkylene group, in which, when the number of carbon atoms is at least 2, there are optionally 1 or 2 non-adjacent double bonds; 1 to 3 non-adjacent methylene groups are optionally replaced by NR1 (where R1 is H, alkyl, or acyl), O, or S; and 1 or 2 methylene groups are optionally replaced by a carbonyl or hydroxymethylene group and pharmaceutically acceptable esters or salts of the compounds and wherein the inflammatory process results from a disease selected from the group consisting of ulcerative colitis, endotoxic shock, rheumatoid arthritis, juvenile arthritis, osteoarthritis, psoriasis, Crohn's disease, inflammatory bowel disease, multiple sclerosis, insulin dependent diabetes mellitus, gout, psoriatic arthritis, reactive arthritis, vital or post-viral arthritis and ankylosing spondylarthritis.
대표청구항▼
1. A method of inhibiting the inflammatory process, the method comprising administering to a mammal suffering from inflammation a therapeutically effective amount of a pharmaceutical composition comprising a compound where:R is a C1-C10 alkylene group, in which, when the number of carbon atoms is at
1. A method of inhibiting the inflammatory process, the method comprising administering to a mammal suffering from inflammation a therapeutically effective amount of a pharmaceutical composition comprising a compound where:R is a C1-C10 alkylene group, in which, when the number of carbon atoms is at least 2, there are optionally 1 or 2 non-adjacent double bonds; 1 to 3 non-adjacent methylene groups are optionally replaced by NR1 (where R1 is H, alkyl, or acyl), O, or S; and 1 or 2 methylene groups are optionally replaced by a carbonyl or hydroxymethylene group, with the proviso that if R is unsaturated then the carbonyl is not adjacent to either aromatic ring, and pharmaceutically acceptable esters or salts of the compounds. 2. The method of claim 1 where the compound is selected from the group consisting of; 3,4,3′,4′-tetrahydroxybenzoin (compound 1);3,4,3′,4′-tetrahydroxydesoxybenzoin (compound 2);3,4,3′,4′-tetrahydroxydiphenylmethane (compound 3);1,2-bis(3,4-dihydroxyphenyl)ethane (compound 4);1,3-bis(3,4-dihydroxyphenyl)propane (compound 5);N,N′-bis(3,4-dihydroxybenzyl)-N,N1-dimethylethylenediamine (compound 10);N,N′-bis(3,4-dihydroxybenzoyl)-N,N′-dimethylethylenediamine (compound 24);1,2-bis(3,4-dihydroxyphenoxy)ethane (compound 41);1,3-bis(3,4-dihydroxyphenoxy)propane (compound 42);N-(3,4-dihydroxybenzyl)-3-(3,4-dihydroxyphenoxy)-2-hydroxyropylamine (compound 44);3,4-dihydroxyphenoxyacetic acid 3,4-dihydroxyanilide (compound 45);3,4-dihydroxyphenoxyacetic acid 3,4-dihydroxybenzylamide (compound 46);3,4-dihydroxyphenoxyacetic acid 3,4-dihydroxyphenethylamide (compound 47);3,4-dihydroxybenzoic acid 3,4-dihydroxyanilide (compound 51);3,4-dihydroxybenzoic acid 3,4-dihydroxybenzylamide (compound 52);3,4-dihydroxybenzoic acid 3,4-dihydroxyphenethylamide (compound 53);3,4-dihydroxyphenylacetic acid 3,4-dihydroxyanilide (compound 54);3,4-dihydroxyphenylacetic acid 3,4-dihydroxybenzylamide (compound 55);3,4-dihydroxyphenylacetic acid 3,4-dihydroxyphenethylamide (compound 56);3-(3,4-dihydroxyphenyl)propionic acid 3,4-dihydroxyanilide (compound 57);3-(3,4-dihydroxyphenyl)propionic acid 3,4-dihydroxybenzaylamide (compound 58);3-(3,4-dihydroxyphenyl)propionic acid 3,4-dihydroxyphenethylamide (compound 59);3,4-dihydroxycinnamic acid 3,4-dihydroxyanilide (compound 60);3,4-dihydroxycinnamic acid 3,4-dihydroxybenzylamide (compound 61);3,4-dihydroxycinnamic acid 3,4-dihydroxyphenethylamide (compound 62);oxalic acid bis(3,4-dihydroxyanilide) (compound 63);oxalic acid bis(3,4-dihydroxybenzylamide) (compound 64);oxalic acid bis(3,4-dihydroxyphenethylamide) (compound 65);succinic acid bis(3,4-dihydroxyanilide) (compound 66);succinic acid bis(3,4-dihydroxybenzylamide) (compound 67);succinic acid bis(3,4-dihydroxyphenethylamide) (compound 68);maleic acid bis(3,4-dihydroxyanilide) (compound 69);maleic acid bis(3,4-dihydroxyanilide) (compound 70);fumaric acid bis(3,4-dihydroxyanilide) (compound 71);fumaric acid bis(3,4-dihydroxybenzylamide) (compound 72);bis(3,4-dihydroxybenzyl)amine (compound 73);N(3,4-dihydroxybenzyl)-3,4-dihydroxyphenethylamine (compound 74);1,3-bis(3,4-dihydroxybenzyl)urea (compound 76);1-(3,4-dihydroxyphenyl)-3-(3,4-dihydroxybenzyl)urea (compound 77);1-(3,4-dihydroxybenzyl)-3-(3,4-dihydroxyphenethyl)urea (compound 78);and methylenedioxy analogs and pharmaceutically acceptable esters or salts of the compounds. 3. The method of claim 1 where the mammal is human. 4. The method of claim 1 where the therapeutically effective amount of the pharmaceutical composition is from 0.1-1000 mg/Kg body weight/day. 5. The method of claim 1 where the therapeutically effective amount of the pharmaceutical composition is from 1-100 mg/Kg body weight/day. 6. The method of claim 1 where the therapeutically effective amount of the pharmaceutical composition is from 10-100 mg/Kg body weight/day. 7. The method of claim 1 wherein the inflammatory process results from a disease selected from the group consisting of ulcerative colitis, endotoxic shock, rheumatoid arthritis, juvenile arthritis, osteoarthritis, psoriasis, Crohn's disease, inflammatory bowel disease, multiple sclerosis, insulin dependent diabetes mellitus, gout, psoriatic arthritis, reactive arthritis, viral or post-viral arthritis and ankylosing spondylarthritis. 8. The method of claim 7 wherein the inflammatory process results from rheumatoid arthritis. 9. The method of claim 1 where the pharmaceutical composition additionally comprises one or more pharmaceutically acceptable excipients.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (42)
Felsenstein Kevin (Madison CT) Smith David W. (Madison CT) Poss Michael A. (Lawrenceville NJ) Chaturvedula Prasad (Cheshire CT) Sloan Charles P. (Wallingford CT), 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of b
상세보기
Marchbanks Roger Michael,GB2 ITX SW4 9EX, Alzheimer's disease treatment with tacrine metabolites.
Kuznicki James Thaddeus (Cincinnati OH) Turner Lana Sandman (Cincinnati OH), Beverage compositions containing green tea solids, electrolytes and carbohydrates to provide improved cellular hydration.
Bombardelli Ezio (Milan ITX) Patri Gianfranco (Milan ITX) Pozzi Roberto (Milan ITX), Complexes of saponins and their aglycons with phospholipids and pharmaceutical and cosmetic compositions containing them.
Snow, Alan D; Nguyen, Beth; Castillo, Gerardo; Sanders, Virginia; Lake, Thomas; Larsen, Lesley; Weavers, Rex T; Lorimer, Stephen; Larsen, David; Coffen, David L; Coffen, legal representative, Charlotte, Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease.
Snow, Alan D.; Nguyen, Beth P.; Castillo, Gerardo M.; Sanders, Virginia J.; Lake, Thomas P.; Larsen, Lesley; Weavers, Rex T.; Lorimer, Stephen D.; Larsen, David S.; Coffen, David L.; Coffen, legal representative, Charlotte, Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease.
Snow, Alan D.; Nguyen, Beth P.; Castillo, Gerardo M.; Sanders, Virginia J.; Lake, Thomas P.; Larsen, Lesley; Weavers, Rex T.; Lorimer, Stephen D.; Larsen, David S.; Coffen, legal representative, Charlotte; Coffen, David L., Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease.
Snow, Alan D.; Nguyen, Beth P.; Castillo, Gerardo M.; Sanders, Virginia J.; Lake, Thomas P.; Larsen, Lesley; Weavers, Rex T.; Lorimer, Stephen D.; Larsen, David S.; Coffen, David L.; Coffen, legal representative, Charlotte, Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Marshall Lucia G. I. (St. Charles MO) Patel Kanaiyalal R. (St. Louis MO) Roufa Dikla G. (St. Louis MO), Controlled release formulations of trophic factors in ganglioside-lipsome vehicle.
Mohr Judy M. (Menlo Park CA) Baker Richard W. (Palo Alto CA) Nakaji Lisa A. (San Jose CA), Liquid reservoir transdermal patch for the administration of ketorolac.
Castillo, Gerardo; Snow, Alan D., Methods for inhibiting and reducing amyloid fibril formation associated with Alzheimer's Disease and other amyloidoses.
Keplinger Klaus (Innsbruck ATX) Wagner Hildebert (Breitbrunn am Chiemsee DEX) Kreutzkamp Barbara (Munich DEX), Oxindole alkaloids having properties stimulating the immunologic system.
Keplinger Klaus (Mullerstrasse 30 A-6020 Innsbruck ATX) Keplinger Dietmar (Innsbruck ATX), Oxindole alkaloids having properties stimulating the immunologic system & preparation containing the same.
Keplinger Klaus (Mllerstrasse 30 A-6020 Innsbruck ATX) Wagner Hildebert (Breitbrunn am Chiemsee DEX) Kreutzkamp Barbara (Munich DEX), Oxindole alkaloids having properties stimulating the immunologic system and preparation containing the same.
Santus Giancarlo (Milan ITX) Bilato Ettore (Padua ITX) Lazzarini Gabriele (Pero ITX), Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension.
Le Grazie Cristina (Milan ITX), Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutic.
Coffen David L. (Glenridge NJ) Kalaritis Panayiotis (New Providence NJ) Patridge John J. (Upper Montclair NJ), Production of 2-hydroxy substituted arylalkanoic acids and esters by enzymatic hydrolysis.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.